TY - JOUR
T1 - Growth factors in the treatment of wasting in kidney failure
AU - Chen, Yu
AU - Fervenza, Fernando C.
AU - Rabkin, Ralph
N1 - Funding Information:
*Assistant Professor Medicine, Peking University First Hospital, Beijing, China. \]'Assistant professor Medicine, Mayo Clinic, Rochester, BAN. +÷professor Medicine/Nephrology, Stanford University, and Research Service Veterans Affairs Palo Alto Health Care System, Palo Alto, CA. Support was provided by funds from the Research Service of the Department of Veterans Affairs and National Institute of Health R21 DK 53613. Address reprint requests to Ralph Rabkin, BAD, VAPAHCS (111R), 3801 Miranda Ave, Palo Alto, CA 94304. © 2001 by the National Kidney Foundation, Inc. 1051-2276/01/1102-0002835.00/0 doi: 10.1053/jren. 2001.23468
PY - 2001/4
Y1 - 2001/4
N2 - Protein-energy malnutrition is relatively common in patients with advanced renal failure and is associated with an increase in morbidity and mortality. Accordingly, there is a need to develop more effective treatments to enhance the nutritional status of these patients. One such approach is the use of recombinant growth factors and anabolic steroids for malnourished patients refractory to standard nutritional therapy. In this article, we review the current state of our knowledge regarding the potential use of these agents in malnourished renal failure patients and conclude that although the studies performed to date are indeed encouraging, further and more extensive clinical trials are required to firmly establish their efficacy and safety profile and the indications for clinical use.
AB - Protein-energy malnutrition is relatively common in patients with advanced renal failure and is associated with an increase in morbidity and mortality. Accordingly, there is a need to develop more effective treatments to enhance the nutritional status of these patients. One such approach is the use of recombinant growth factors and anabolic steroids for malnourished patients refractory to standard nutritional therapy. In this article, we review the current state of our knowledge regarding the potential use of these agents in malnourished renal failure patients and conclude that although the studies performed to date are indeed encouraging, further and more extensive clinical trials are required to firmly establish their efficacy and safety profile and the indications for clinical use.
UR - http://www.scopus.com/inward/record.url?scp=0035315915&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0035315915&partnerID=8YFLogxK
U2 - 10.1053/jren.2001.23468
DO - 10.1053/jren.2001.23468
M3 - Review article
C2 - 11295025
AN - SCOPUS:0035315915
SN - 1051-2276
VL - 11
SP - 62
EP - 66
JO - Journal of Renal Nutrition
JF - Journal of Renal Nutrition
IS - 2
ER -